The antibiotic which can cause respiratory failure when used in patients with myasthenia gravis is:
**Core Concept**
Aminoglycoside antibiotics can exacerbate neuromuscular junction disorders by blocking acetylcholine release at the motor endplate, leading to muscle weakness and respiratory failure. This is particularly concerning in patients with myasthenia gravis, an autoimmune disorder characterized by antibodies against acetylcholine receptors.
**Why the Correct Answer is Right**
Aminoglycosides, such as gentamicin, inhibit the release of acetylcholine from the motor neuron terminal by binding to the calcium channels, thereby reducing the amount of acetylcholine available for receptor binding. This action mimics the effect of myasthenia gravis antibodies, which already impair acetylcholine receptor function. As a result, patients with myasthenia gravis are at increased risk of respiratory failure when treated with aminoglycosides.
**Why Each Wrong Option is Incorrect**
**Option A:** Aminocaproic acid is an antifibrinolytic agent that does not affect neuromuscular transmission.
**Option B:** Ceftriaxone is a cephalosporin antibiotic that does not have a significant effect on neuromuscular function.
**Option C:** Vancomycin is a glycopeptide antibiotic that can cause nephrotoxicity and ototoxicity but does not affect neuromuscular transmission.
**Clinical Pearl / High-Yield Fact**
Aminoglycosides should be used with caution in patients with neuromuscular disorders, and alternative antibiotics should be considered when possible. If aminoglycosides are necessary, monitoring of neuromuscular function and respiratory status is crucial.
**Correct Answer: A. Gentamicin**